Argenx halts Phase 3 Sjögren's trial as celiac disease data brings mixed results

Argenx disclosed on Thursday that it is ending its Phase 3 trial in Sjögren's syndrome after the study failed to meet its primary endpoint.

The decision came alongside the release of encouraging results from a separate celiac disease program, where the drug showed statistically significant improvement in key biomarkers.

Investors reacted sharply, with Argenx shares falling in trading following the announcement, reflecting concern over the setback in the Sjögren's program.

The mixed outcome highlights the volatility of autoimmune drug development and leaves the company focused on advancing the celiac candidate while reassessing its Sjögren's strategy.